ARGX
Price
$875.76
Change
-$14.29 (-1.61%)
Updated
Oct 22 closing price
Capitalization
54.79B
132 days until earnings call
Intraday BUY SELL Signals
BRNS
Price
$0.74
Change
-$0.02 (-2.63%)
Updated
Sep 8 closing price
Capitalization
30.23M
13 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARGX vs BRNS

ARGX vs BRNS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ARGX vs. BRNS commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARGX is a Hold and BRNS is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ARGX with price predictions
Oct 22, 2026

ARGX's RSI Indicator ascending out of oversold territory

The RSI Oscillator for ARGX moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 20 similar instances when the indicator left oversold territory. In 15 of the 20 cases the stock moved higher. This puts the odds of a move higher at 75%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on ARGX as a result. In 63 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.

The Moving Average Convergence Divergence (MACD) for ARGX just turned positive on October 21, 2026. Looking at past instances where ARGX's MACD turned positive, the stock continued to rise in 36 of 49 cases over the following month. The odds of a continued upward trend are 73%.

Following a +7.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARGX advanced for three days, in 217 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.

ARGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

ARGX moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ARGX crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.

The Aroon Indicator for ARGX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 18 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. ARGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 69 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.509) is normal, around the industry mean (2.973). P/E Ratio (31.559) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (1.189) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (12.330) is also within normal values, averaging (438.009).

A.I.Advisor
a Summary for BRNS with price predictions
Oct 22, 2026

BRNS sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for BRNS moved above the 200-day moving average on September 28, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 22, 2026. You may want to consider a long position or call options on BRNS as a result. In 98 of 116 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 22 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Aroon Indicator for BRNS entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.530) is normal, around the industry mean (2.973). P/E Ratio (-0.726) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (2.165) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. BRNS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BRNS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ARGX: Fundamental Ratings
ARGX
OUTLOOK RATING
1..100
9
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
PROFIT vs RISK RATING
1..100
18
SMR RATING
1..100
41
PRICE GROWTH RATING
1..100
57
P/E GROWTH RATING
1..100
69
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ARGXBRNS
RSI
ODDS (%)
Bullish Trend 1 day ago
75%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
62%
Bearish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
73%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
62%
Bullish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 2 days ago
71%
N/A
Declines
ODDS (%)
Bearish Trend 10 days ago
63%
N/A
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
73%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
59%
Bearish Trend 1 day ago
88%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (ARGX: $875.76 vs. BRNS: $0.74)
Brand notoriety: ARGX and BRNS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARGX: 321% vs. BRNS: 131%
Market capitalization -- ARGX: $54.79B vs. BRNS: $30.23M
ARGX [@Biotechnology] is valued at $54.79B. BRNS’s [@Biotechnology] market capitalization is $30.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARGX’s FA Score shows that 1 FA rating(s) are green while BRNS’s FA Score has 0 green FA rating(s).

  • ARGX’s FA Score: 1 green, 4 red.
  • BRNS’s FA Score: 0 green, 5 red.
According to our system of comparison, both ARGX and BRNS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARGX’s TA Score shows that 5 TA indicator(s) are bullish while BRNS’s TA Score has 2 bullish TA indicator(s).

  • ARGX’s TA Score: 5 bullish, 5 bearish.
  • BRNS’s TA Score: 2 bullish, 2 bearish.
According to our system of comparison, both ARGX and BRNS are a good buy in the short-term.

Price Growth

ARGX (@Biotechnology) experienced а +3.48% price change this week, while BRNS (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

ARGX is expected to report earnings on Mar 04, 2027.

BRNS is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ARGX
Daily Signal:
Gain/Loss:
BRNS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

BRNS and

Correlation & Price change

A.I.dvisor indicates that over the last year, BRNS has been loosely correlated with NGNE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if BRNS jumps, then NGNE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BRNS
1D Price
Change %
BRNS100%
N/A
NGNE - BRNS
51%
Loosely correlated
-6.90%
NEUP - BRNS
50%
Loosely correlated
N/A
TARA - BRNS
35%
Loosely correlated
-2.40%
BGMS - BRNS
31%
Poorly correlated
-5.62%
ARGX - BRNS
29%
Poorly correlated
-1.61%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
STZ138.986.96
+5.27%
Constellation Brands
FFBC32.470.82
+2.59%
First Financial Bancorp
CARE30.700.33
+1.09%
Carter Bankshares
CRDL1.15-0.02
-1.71%
Cardiol Therapeutics
BNKK1.04-0.19
-15.45%
Bonk Inc.